The gap most teams recognise
Most rare disease teams already understand JCA. They have task forces, internal training, methodology decks, and partners ready to support dossier preparation when the time comes.
What’s harder – and what actually determines whether a JCA goes well – is whether teams think like JCA when decisions on live assets are being made. Comparator selection. Endpoint hierarchy. Population definition. Patient evidence framing. These choices are shaped now, often in protocol meetings and global development conversations where EU access perspectives are not yet in the room. By the time formal JCA preparation begins, they are largely fixed.
That is a behavioural problem, not a knowledge problem. And behavioural problems are not solved by another framework or training deck. They are solved by getting the right thinking into the right room at the right moment – and making sure someone owns it at asset level.
Why the stakes have shifted
Until recently, a weak JCA outcome was a European market access problem. The April 2026 Most-Favored-Nation executive order has changed that.
US drug prices for innovative medicines are now linked to the lowest prices observed across a basket of reference countries – and EU member states sit squarely in that basket. Which means EU reimbursement prices, shaped directly by JCA outcomes, now feed into what a company may be required to accept on the same asset in the US.
For US-based biotech in particular, this changes the calculus considerably. A JCA outcome that gives EU payers reason to push prices down no longer just affects European revenue. It affects US revenue on the same asset.
The cost of waiting on upstream JCA readiness has materially shifted.
Where RAREready sits
RAREready works upstream of HEOR, regulatory and submission partners. We are not a methodology firm – our work sits earlier, on the decisions, ownership and internal alignment that determine whether downstream evidence work lands as intended.
Five questions worth sitting with
- How do you ensure JCA thinking is visible at the moments when key asset decisions are being shaped?
- How do EU perspectives reach global decision-makers early enough to influence decisions – particularly where those decisions sit outside EU functions?
- Who owns JCA thinking at asset level – and how is that made clear across functions?
- How do you apply JCA thinking upstream, rather than as a layer added on top of existing HTA processes?
- How do you approach areas such as patient input and COI in a JCA context, where expectations are still forming?
If these questions are starting to surface inside your organisation, the conversation worth having begins there.
Who we work with
- Rare disease and ATMP programme leads
- EU and Global Market Access and Policy
- Medical Affairs
- Patient Engagement & Advocacy
- Evidence and Clinical teams
- Affiliates
- US biotechs preparing for Europe – where MFN has made the EU readiness conversation a board-level question
What we do not do
RAREready is focused and deliberately narrow in scope.
We do not write JCA dossiers or submissions. We do not conduct HEOR modelling, indirect treatment comparisons or formal PICO analysis. We do not deliver regulatory strategy or EMA submissions. We do not replace your existing HTA or market access partners.
We work upstream of all of this – on the decisions, ownership and internal alignment that determine whether downstream evidence work lands as intended.
We work as a focused, senior team. The people you speak to at the outset are the people who deliver.
A 20-minute call is often enough to understand what is most relevant and where to start.
Recent thinking
EU Joint Clinical Assessment (JCA) in Rare Disease
Where synchronised EU scrutiny changes internal exposure and governance design → Read on swii.ch
EU JCA is Underway
A shared EU evaluation of evidence has begun. See what it means for rare-disease sponsors and why patient evidence will define future success. → Read on swii.ch
EU JCA Readiness: Why 2026 Changes Planning
What early implementation signals reveal about PICO decisions and upstream ownership → Read on swii.ch
5 Patient Evidence Myths That Undermine EU JCA Strategy
Common structural misunderstandings that weaken comparative positioning → Read on swii.ch
Next Steps
A 20-minute call is often enough to understand your needs and identify the right starting point.
Contact us
We’re here to help rare-disease innovators prepare effectively for EU JCA and patient-centred evidence needs.
EU JCA & HTA Regulation (HTAR)
Frequently Asked Questions
Yes – and these are often the teams who benefit most. Task forces give you the awareness. HEOR partners do the methodology work. Our work sits between those two: making sure JCA thinking is visible inside live asset decisions before the methodology partners arrive and build on foundations that haven’t been tested. We work comfortably alongside existing partners and complement, rather than replace, them.
Most engagements begin with one or two asset-level working sessions over four to six weeks, focused on real decisions on live assets with your US and EU colleagues. From there, teams often choose to develop a concise decision aid for use at key milestones, or a broader organisational playbook. We work with a small, senior team throughout – the people you meet at the outset are the people who deliver.
Yes – and arguably more urgent than for EU-headquartered teams. The April 2026 MFN executive order has connected EU reference prices directly to US pricing exposure, which means a weak JCA outcome on a lead asset is no longer just a European access issue. We work with US-based biotech to bring EU access perspectives into global development and commercial conversations early, before the decisions that JCA will read most closely have hardened.
A 20-minute conversation is usually enough to confirm whether the work is relevant for where you are. If it’s not the right moment, we’ll say so. We don’t enrol you in an automated follow-up sequence — the decision sits with you.